TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02947490

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Self BP measurement
Description: BP home measurement by patient, results to GP and GP alters treatment as per usual practice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Self BP measurement and patient management of anti-hypertensive treatment altering their own medication under supervision depending on home BP measurements

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Self BP measurement and patient management of anti-hypertensive treatment altering their own medication under supervision depending on home BP measurements

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard BP management
Description: GP to measure BP and manage BP control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: Contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels.
Study: NCT02959970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapsone gel
Description: Dapsone (ACZONE) 7.5% gel topically once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapsone gel
Description: Dapsone (ACZONE) 7.5% gel topically once daily.
Study: NCT02027974

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Iconacy Hip System
Description: Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker Accolade Hip System
Description: Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
Study: NCT02791867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AphoelineBrake
Description: The study is proposed as a placebo controlled randomized controlled trial with an intervention (AphoelineBrake) in addition to their standard treatment in comparison to a standard treatment control arm receiving an identical placebo. Prior to the commencement of any study procedures, participants will document informed consent and acknowledgement of privacy rights. Participants will be seen for initial consenting procedures, initial study procedures, and follow-up procedures at the Dasman Diabetes Institute clinic.Scheduled study visits will occur at Day 0, Day 7, Months: 1, 3, 6, 9, and 12 months in accordance with standards of medical care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AphoelineBrake
Description: The study is proposed as a placebo controlled randomized controlled trial with an intervention (AphoelineBrake) in addition to their standard treatment in comparison to a standard treatment control arm receiving an identical placebo. Prior to the commencement of any study procedures, participants will document informed consent and acknowledgement of privacy rights. Participants will be seen for initial consenting procedures, initial study procedures, and follow-up procedures at the Dasman Diabetes Institute clinic.Scheduled study visits will occur at Day 0, Day 7, Months: 1, 3, 6, 9, and 12 months in accordance with standards of medical care.
Study: NCT01391468

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cornstarch
Description: placebo will be given in 6 months
Study: NCT03207724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xilonix plus Onivyde and 5FU
Description: Xilonix by IV
Study: NCT03444467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC9204-1513
Description: Participants will receive NNC9204-1513 subcutaneous (s.c., in to a skin fold on the stomach) injection as single increasing doses of 0.01 mg, 0.04 mg, 0.10 mg, 0.25 mg, 0.50 mg, 1.0 mg or 2.0 mg. Each participant will only be given one dose.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Participants will receive single dose of 1 mg glucagon s.c. injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive single dose of placebo (for double dummy injections).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive single dose of placebo (for double dummy injections).
Study: NCT00095810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: Tablets, Oral, 1-10mg, Once daily, 6 weeks.
Study: NCT04371185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT2206
Description: 45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stelara(US-licensed)
Description: 45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stelara(EU-licensed)
Description: 45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
Study: NCT01025297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-7
Description: 3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week
Study: NCT02715596

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA supplementation
Description: 2.7 g EPA supplementation in a 15 cc emulsion stick-pack

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo in 15 cc emulsion stick-pack
Study: NCT03582969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal transplantation
Description: Fecal transplantation administered orally via frozen capsules.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT01851525

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThermoCoolSmartTouch ablation catheter, Biosense Webster

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThermoCoolSmartTouch ablation catheter, Biosense Webster
Study: NCT00656578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4975
Description: Single dose, solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, solution
Study: NCT02100410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A toric contact lens T1
Description: Iteration 2-87-1 with embossed mark

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A toric contact lens T2
Description: Iteration 2-87-1 without embossed mark

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A toric contact lens T3
Description: Iteration 2-87-2 with embossed mark

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A toric contact lens T4
Description: Iteration 2-87-2 without embossed mark

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A toric contact lens T5
Description: Iteration 2-87-3 with embossed mark

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A toric contact lens T6
Description: Iteration 2-87-3 without embossed mark
Study: NCT03904576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study: NCT02106104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg QD (N=24)
Description: Linagliptin 5 mg will be taken orally, once daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride 1 mg QD (N=24)
Description: Glimepiride 1 mg will be taken orally, once daily for 8 weeks
Study: NCT00516958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Dermacyn
Description: Topical Dermacyn once a day for 10 Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Dermacyn and Levofloxacin
Description: Topical Dermacyn once a day and levofloxacin 750 mg PO per day; both for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Saline and Levofloxacin
Description: Topical saline once a day and levofloxacin 750 mg PO daily, both for 10 days
Study: NCT02622438

Intervention type: OTHER
Group type: OTHER
Intervention: Followed with an initial assessment, six months and followed annually for 3 years corresponding to the usual follow-up of the patient.
Study: NCT03503812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (1) for outdoor exposure reduction - Asthma in Children
Description: Intervention 1 (I1) aims to reduce exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (2) for outdoor and indoor exposure reduction - Asthma in Children
Description: Intervention 2 (I2) aims to reduce both:~i) exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity~   ii) indoor particle levels on a continuous daily basis throughout the follow-up DDS period. This intervention will consist of two recommendations for participants' schools and houses:~3. Reduce particle infiltration into residences by keeping windows and doors closed as much as possible and~4. Reduce indoor particle levels by using air cleaners.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (1) for outdoor exposure reduction - Atrial Fibrillation
Description: Intervention 1 (I1) aims to reduce exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (2) for outdoor and indoor exposure reduction - Atrial Fibrillation
Description: Intervention 2 (I2) aims to reduce both:~i) exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity~   ii) indoor particle levels on a continuous daily basis throughout the follow-up DDS period. This intervention will consist of two recommendations for participants' houses:~3. Reduce particle infiltration into residences by keeping windows and doors closed as much as possible and~4. Reduce indoor particle levels by using air cleaners.
Study: NCT03043261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Williams LifeSkills
Description: Online multi-media interactive training modules which address 10 core skills to improve coping, stress management and interpersonal relationships.
Study: NCT01364857

Intervention type: GENETIC
Group type: OTHER
Intervention: search for polymorphisms of RASA1 gene
Description: Blood sample ( 5 mL) at tne inclusion of the child DNA extraction and genetic analysis of the 24 exons of RASA1 gene after specific consent
Study: NCT04536493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (1 application)
Description: 1 application of LET topical anesthetic gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (3 applications)
Description: 3 applications of LET topical anesthetic gel
Study: NCT03193450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based re-education
Description: Patients will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: First education at the clinic
Description: Patients will receive an instruction card about the drug administration at the clinic by doctors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: First education at the clinic
Description: Patients will receive an instruction card about the drug administration at the clinic by doctors.
Study: NCT01911208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RECRUIT intervention
Description: Sites randomized to RECRUIT are taught skills to develop a tailored recruitment intervention encompassing continuous quality improvement and patient navigation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Non-intervention control.
Study: NCT04216706

Intervention type: DRUG
Intervention: tailored pharmaceutical treatment
Description: Tailored medication is advised in women with inadequate hemodynamic adaptation to pregnancy. Type of medication depends on total peripheral vascular resistance and heart rate. In short, women with a low peripheral vascular resistance in parallel with a high heart rate are advised a betablocker (labetalol), while a vasodilating agent (calcium channel blocker, nifedipine) was advised in women with a high total peripheral vascular resistance in combination with a low heart rate. Women with suboptimal adaptation to pregnancy without an extreme pronounced vascular profile are advised a centrally acting sympatholytic agent (methyldopa).
Study: NCT03273231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% saline solution
Study: NCT01402388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group lifestyle programme
Study: NCT03081572

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet aggregation
Description: Platelet aggregation

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet aggregation
Description: Platelet aggregation
Study: NCT01522560

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Feedback group
Description: Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.~This group is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the Multiscore Feedback (MSF).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.
Study: NCT00260195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-based cognitive behavioral support group
Study: NCT02457299

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two Stage Esophagectomy
Description: Patients will undergo laparoscopic staging and ischemic gastric conditioning and pyloric Botox injection 7-10 days prior to an esophagectomy with gastric pull-up reconstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One Stage Esophagectomy
Description: Patients will undergo an esophagectomy with gastric pull-up reconstruction without any preconditioning.
Study: NCT03023605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Intervention for PE Diagnosis
Description: Focused on the Emergency Department staff and the rotating residents during the months 4 and 5 of 2015, and consisted of:~1. Clinical Update Sessions for staff ED (20 physicians)~2. training sessions for residents that rotate in ED (60 physicians )~3. Development of a triptych, including clinical prediction scales, combination algorithm of scales and D-Dimmer value~4. Development of posters, with brief information~5. Dissemination by e-mail of scientific information~6. Direct reminder during the working day
Study: NCT01989572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00442039

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the third phase, which is the Discontinuation Phase, patients will be randomized to either placebo or lithium treatment for up to 28 weeks.
Study: NCT03555331

Intervention type: BEHAVIORAL
Intervention: Child Safety Control Intervention
Description: In the study period which spanned from early infancy through age 3 years, the child safety intervention group was given an educational program with messages focused on child and home safety, guided by the American Academy of Pediatrics and the Academy's guide for health supervision, Bright Futures. The observation-only study extension will not include any intervention, rather it will assess any long term outcomes from the education given to parents when their children were 0-2 years old.

Intervention type: BEHAVIORAL
Intervention: Responsive Parenting Intervention
Description: During infancy, the Responsive Parenting group was given an educational program containing messages providing developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle aimed at preventing rapid weight gain in infancy and overweight at age 3 years. The new study period will not include any intervention, rather it will assess any long term outcomes from the education given to parents when their children were 0-2 years old.
Study: NCT03052127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light-activated AU-011
Description: Study treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light-activated AU-011
Description: Study treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light-activated AU-011
Description: Study treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light-activated AU-011
Description: Study treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light-activated AU-011
Description: Study treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light-activated AU-011
Description: Study treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light-activated AU-011
Description: Study treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light-activated AU-011
Description: Study treatment
Study: NCT01989572

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03052127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light-activated AU-011
Description: Study treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light-activated AU-011
Description: Study treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light-activated AU-011
Description: Study treatment
Study: NCT01989572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given GM-CSF placebo SC
Study: NCT03052127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light-activated AU-011
Description: Study treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Activation
Description: Study treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Activation
Description: Study treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Activation
Description: Study treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Activation
Description: Study treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Activation
Description: Study treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Activation
Description: Study treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Activation
Description: Study treatment
Study: NCT01989572

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given GM-CSF placebo SC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given GM-CSF placebo SC
Study: NCT03052127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Activation
Description: Study treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Activation
Description: Study treatment
Study: NCT01989572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given peptide placebo SC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given peptide placebo SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study: NCT03052127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Activation
Description: Study treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Activation
Description: Study treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Activation
Description: Study treatment
Study: NCT02368574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Class II hysterectomy
Description: Class II hysterectomy
Study: NCT02166814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan and Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Study: NCT03552835

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no caries removal
Description: occlusal caries were treated with no caries removal and placement of stainless steel crown

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial caries removal upto soft dentin
Description: occlusal caries were treated by partial caries removal upto soft dentin followed by Glass Ionomer Cement placement as a base and composite restoration
Study: NCT01989572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC